AAA May 2015 – Page 16

Sanofi sets MyoKardia’s heart fluttering for $46m series B

US-based drug developer MyoKardia closed its series B round yesterday, raising $46m from investors including pharmaceutical company Sanofi. Casdin Capital, Cormorant Asset Management, Perceptive Life Sciences, BridgeBio, an unnamed affiliate of Cowen Group and an undisclosed public investment fund also participated in the funding round. MyoKardia is developing treatments for genetic heart diseases, and will… Continue reading Sanofi sets MyoKardia’s heart fluttering for $46m series B